We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

By LabMedica International staff writers
Posted on 01 Dec 2023
Print article
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular disease. While not everyone who suffers from extreme stressors faces health complications later in life, a significant number do. For those affected, their cells tend to age more rapidly, leading to earlier physical breakdowns in the body, a phenomenon known as "accelerated biological aging." Natural aging processes typically involve a decline in cognitive functions, including memory, reasoning, executive function, and processing speed. Although global genetic research has generated mixed findings on whether accelerated biological aging kicks off early cognitive decline, previous studies suggest that early signs of cognitive decline can be identified long before they impact the quality of life. This opens up a window for early detection and intervention.

Now, a new study by researchers at Penn State (University Park, PA, USA) has unveiled genetic markers that could potentially forecast cognitive decline. According to the researchers, future blood tests might be able to detect early cell aging caused by these stressors, indicating a decline in cognitive abilities. In their study, the researchers analyzed two distinct population groups and found that accelerated biological aging might be a useful biomarker for identifying cognitive decline.

Utilizing blood samples and other medical data compiled from other studies, the researchers explored the relationship between potential genetic markers of cognitive performance, actual cognitive testing results, and the history of psychiatric disorders or childhood maltreatment. Their analysis revealed that accelerated biological aging is linked to reduced cognitive abilities and slower processing speed. However, the exact genetic markers indicating this relationship varied between the two study groups. The researchers attribute these differences to the distinct designs of the studies, suggesting that varying genetic markers could signal cognitive decline depending on the study's structure and focus.

“Understanding the connection between accelerated biological aging and cognitive decline may help researchers create treatments that help people who have experienced extreme stressors to experience better health,” said John Felt, assistant research professor in the Center for Healthy Aging and lead author of the study. “Cognitive decline can undermine your personal and professional life, especially for people who also have a psychiatric condition. Our research could lead to blood tests for early identification of cognitive decline and eventually to personalized treatments that support cognitive function in people with accelerated biological aging.”

Related Links:
Penn State 

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.